Dr. Hoos on the Patients That Respond to Ipilimumab

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb describes that roughly 15% of patients have a response to ipilimumab by conventional criteria (which means to shrinking the tumor). Hoos notes that durability is the importance part of the findings with a median duration of 19 months.